AstraZeneca, a major UK drug company, held early talks with Bristol Myers Squibb, a major US drug company, about joining forces in a deal worth about $400 billion. The news was first reported by the Financial Times on August 2, 2026, and confirmed by Bloomberg, CNBC, Reuters, and Investing.com.

The talks were described as preliminary, meaning very early and not final. People familiar with the matter spoke on condition of anonymity because the discussions are private (Bloomberg). A deal could happen soon, but it could also be delayed or fall apart.

AstraZeneca's share price dropped after the news. When a company announces it wants to buy another, its stock often falls. Investors worry about how much it will cost, how it will be paid for, and how hard it will be to merge two big organizations. That is what happened here.

Both companies sell a lot of cancer drugs. AstraZeneca also works in biopharmaceuticals and rare disease treatments (FT). Bristol Myers Squibb also makes significant money from cancer treatments. A combined company would be one of the largest drugmakers in the world by revenue.

At $400 billion, this deal would be bigger than any pharmaceutical merger ever. The largest completed pharma merger so far was Bristol-Myers Squibb's 2019 purchase of Celgene for $74 billion. The biggest pharma deal ever attempted was Pfizer's proposed $160 billion bid for Allergan, which never went through. This potential deal would be more than double that.

Several things make a deal this size very difficult. The US and European governments would review whether the combined company would have too much power, especially in cancer drugs. Regulators could force the companies to sell off some products to keep competition alive, or they could block the deal entirely.

There are also political issues. AstraZeneca is based in Cambridge, UK, and Bristol Myers Squibb is in New York. A British company buying a major American drugmaker would draw attention from politicians in both countries. Drug pricing, supply chains, and where medicines are manufactured are all hot topics right now.

Paying for a $400 billion deal is another challenge. AstraZeneca is valuable, but not enough to pay entirely in cash. It would likely need to offer its own shares as part of the payment, which reduces the value of existing shareholders' stakes. That is part of why the stock dropped. Even a partial cash payment would require borrowing large amounts of money.

Because the talks are only at an early stage, there is no guarantee anything will happen. The sources said the discussions are preliminary and could be delayed or abandoned. Most early-stage talks about big mergers never result in a final deal, and pharmaceutical deals are especially likely to fall apart during government review.

The broader context here is about why a deal this size even came up. A $400 billion combination suggests two companies of similar weight joining together, not one simply buying the other. It signals that AstraZeneca's leaders are thinking about getting much bigger to stay competitive. The drug industry faces challenges like expiring patents (which allow cheaper copycat drugs to enter the market), pressure to lower drug prices, and rising research costs. Whether or not this deal happens, it shows how top pharma executives see size as a way to survive those pressures.

For investors, the question is whether the stock drop already reflects the odds of the deal falling through. If the talks collapse, AstraZeneca shares would likely recover. If they move forward, the stock could keep swinging as each new hurdle comes up. Right now, the market is reacting to an event with only two possible outcomes and very little public information to go on.